Products
Naptumomab Estafenatox Biosimilar Fusion Protein (5T4) for Research
Pre-Made Naptumomab Estafenatox biosimilar, Fusion Protein, Naptumomab-Anti-TPBG Antibody: Anti-5T4/5T4AG/M6P1/WAIF1 therapeutic antibody fused with Staphylococcus aureus enterotoxin E SEA/E120 superantigen (synthetic) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-923-1mg | 1mg | 3090 |
| GMP-Bios-INN-923-10mg | 10mg | |
| GMP-Bios-INN-923-100mg | 100mg | |
| GMP-Bios-INN-923-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Naptumomab Estafenatox biosimilar, Fusion Protein, Naptumomab-Anti-TPBG Antibody: Anti-5T4/5T4AG/M6P1/WAIF1 therapeutic antibody fused with Staphylococcus aureus enterotoxin E SEA/E120 superantigen (synthetic) |
| INN Name | Naptumomab Estafenatox |
| Target | TPBG |
| Format | Fusion Protein |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | Fab - G1 - kappa |
| VD LC | Fab - G1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Active Biotech AB (Lund Sweden) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - TPBG
1. Protein Trophoblast glycoprotein
2. Gene TPBG
3. Organism Homo sapiens (Human)
Function
May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.
Miscellaneous
Antigen 5T4 is overexpressed by a wide spectrum of cancers, including colorectal, ovarian and gastric, but with a limited normal tissue expression. Could be used for tumor immunotherapy.
Reduction of TPBG levels by siRNA significantly enhanced the beta-catenin/TCF transcription-based reporter pBAR activation in response to Wnt stimulation.
